Impact of SARS-CoV-2 vaccination on cancer trends: a nationwide interrupted time series study
- 1Department of Preventive Medicine, Korea University College of Medicine
- 2Institute for Future Public Health, Graduate School of Public Health, Korea University
Abstract
Background A recent population-based cohort study of Seoul residents in South Korea reported increased incidence of several cancers within one year of SARS-CoV-2 vaccination. We examined whether a short-term, population-level change in cancer incidence trends was detectable at the national vaccination rollout, using a design that does not compare vaccinated with unvaccinated individuals. Methods We conducted an interrupted time series analysis of Korea National Health Insurance Service data for 36,024,394 individuals born between 1955 and 2004, covering February 2011 to September 2025 (176 months). The intervention point was August 2021, when cumulative first-dose coverage exceeded 50%. Monthly incidence of 13 cancer categories defined by ICD-10 code ranges and of four site-specific cancers (stomach, colorectum, lung and prostate) was compared with counterfactual forecasts from ARIMA/SARIMA models, and segmented regression estimated immediate level and trend changes (significance threshold P < 0.01). The placement of the intervention point was varied from 0 to 18 months, and the resulting estimates were compared with those obtained at 30 placebo points in the pre-pandemic period. Results Overall, 89.3% of the population received at least one dose. No immediate level change (relative risk 0.923–1.072) or trend change (0.995–1.005) reached significance for any of the 13 categories, and none reached significance for the four site-specific cancers. Across the lag grid, 2.0% of estimates met the threshold, compared with 4.1% at placebo points. The 99% confidence limits excluded immediate increases larger than 8.9% to 23.0% across the 13 categories and 8.1% to 23.4% across the four site-specific cancers. Conclusions The national SARS-CoV-2 vaccination rollout in South Korea was not accompanied by a detectable short-term, population-level change in cancer incidence trends over the 50 months that followed. Trial registration Not applicable.
Related
- Breast reconstruction and breast cancer surgery in Brazil's public health system: a nationwide interrupted time-series analysis, 2008-2024.
- Impact of the COVID-19 Pandemic on Inpatient Colorectal Cancer Treatment in Japan: An Interrupted Time Series Analysis Using a National Administrative Database.
- Impact of Chile’s Explicit Health Guarantees Policy on breast cancer mortality: an interrupted time series analysis (1990–2024)
- Hospital-Based Incidence Trends of Thyroid Cancer in Poland: Temporal Trends, Regional Disparities and Demographic Characteristics Based on a Nationwide Hospital Discharge Database (2012-2024).
- Real-world trends in radiotherapy modalities for esophageal cancer: analysis of a nationwide claims database in Japan
BibTeX
@article{na2026impact,
title = {{Impact of SARS-CoV-2 vaccination on cancer trends: a nationwide interrupted time series study}},
author = {Yewon Na and Munkhzul Radnaabaatar and Jaehun Jung},
journal = {Biomarker Research},
year = {2026},
month = oct,
doi = {10.1186/s40364-026-01027-6},
url = {https://doi.org/10.1186/s40364-026-01027-6},
note = {CC BY},
}
RIS
TY - JOUR
TI - Impact of SARS-CoV-2 vaccination on cancer trends: a nationwide interrupted time series study
AU - Yewon Na
AU - Munkhzul Radnaabaatar
AU - Jaehun Jung
PY - 2026
DA - 2026/10/25
JO - Biomarker Research
DO - 10.1186/s40364-026-01027-6
UR - https://doi.org/10.1186/s40364-026-01027-6
AB - Background A recent population-based cohort study of Seoul residents in South Korea reported increased incidence of several cancers within one year of SARS-CoV-2 vaccination. We examined whether a short-term, population-level change in cancer incidence trends was detectable at the national vaccination rollout, using a design that does not compare vaccinated with unvaccinated individuals. Methods We conducted an interrupted time series analysis of Korea National Health Insurance Service data for 36,024,394 individuals born between 1955 and 2004, covering February 2011 to September 2025 (176 months). The intervention point was August 2021, when cumulative first-dose coverage exceeded 50%. Monthly incidence of 13 cancer categories defined by ICD-10 code ranges and of four site-specific cancers (stomach, colorectum, lung and prostate) was compared with counterfactual forecasts from ARIMA/SARIMA models, and segmented regression estimated immediate level and trend changes (significance threshold P < 0.01). The placement of the intervention point was varied from 0 to 18 months, and the resulting estimates were compared with those obtained at 30 placebo points in the pre-pandemic period. Results Overall, 89.3% of the population received at least one dose. No immediate level change (relative risk 0.923–1.072) or trend change (0.995–1.005) reached significance for any of the 13 categories, and none reached significance for the four site-specific cancers. Across the lag grid, 2.0% of estimates met the threshold, compared with 4.1% at placebo points. The 99% confidence limits excluded immediate increases larger than 8.9% to 23.0% across the 13 categories and 8.1% to 23.4% across the four site-specific cancers. Conclusions The national SARS-CoV-2 vaccination rollout in South Korea was not accompanied by a detectable short-term, population-level change in cancer incidence trends over the 50 months that followed. Trial registration Not applicable.
SN - 2050-7771
ER -